Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3ß phosphorylation and p21 down-regulation in hepatocellular carcinoma

Oncotarget

Volumn 4, Issue 10, 2013, Pages 1618-1631

  Giovannini, Catia ^a,b   Baglioni, Michele ^a,b   Baron Toaldo, Marco ^b   Ventrucci, Cristiano ^a   D'Adamo, Stefania ^a   Cipone, Mario ^b   Chieco, Pasquale ^a   Gramantieri, Laura ^a   Bolondi, Luigi ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Angiogenesis; Cell proliferation; Drug resistance; ERK; Notch3

Indexed keywords

DOXORUBICIN; NOTCH3 RECEPTOR; PROTEIN GSK3BETA; PROTEIN P21; SERINE; SHORT HAIRPIN RNA; SORAFENIB; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CANCER PREVENTION; CANCER RESISTANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; UPREGULATION; VALIDATION PROCESS;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOWN-REGULATION; DRUG SYNERGISM; FEMALE; GENE KNOCKDOWN TECHNIQUES; GLYCOGEN SYNTHASE KINASE 3; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MICE; MICE, INBRED NOD; MICE, SCID; NIACINAMIDE; PHENYLUREA COMPOUNDS; PHOSPHORYLATION; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84886739659     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1221     Document Type: Article

References (36)

1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, and Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-390.
2. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, and Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebocontrolled trial. Lancet Oncol. 2009; 10(1):25-34.
3. Gramantieri L, Giovannini C, Lanzi A, Chieco P, Ravaioli M, Venturi A, Grazi GL, and Bolondi L. Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma. Liver Int. 2007; 27(7): 997-1007.
4. Miele L. Notch signaling. Clin Cancer Res. 2006; 12(4): 1074-1079.
5. Weijzen S, Rizzo P, Braid M, Vaishnav R, Jonkheer SM, Zlobin A, Osborne BA, Gottipati S, Aster JC, Hahn WC, Rudolf M, Siziopikou K, Kast WM, and Miele L. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med. 2002; 8(9):979- 986.
6. Weng AP, Nam Y, Wolfe MS, Pear WS, Griffin JD, Blacklow SC, and Aster JC. Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol Cell Biol.2003; 23(2): 655-664.
7. Giovannini C, Gramantieri L, Chieco P, Minguzzi M, Lago F, Pianetti S, Ramazzotti E, Marcu KB, and Bolondi L. Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism. J Hepatol. 2009; 50(5): 969-979.
8. Park JT, Chen X, Trope CG, Davidson B, Shih Ie M, and Wang TL. Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol. 2010;177(3): 1087-1094.
9. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, and Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther.2008; 7(19): 3129-3140.
10. Villanueva A and Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology.2011; 140(5):1410-1426.
11. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, and Trail PA. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64(19): 7099-7109.
12. Huang J, Zhang X, Tang Q, Zhang F, Li Y, Feng Z, and Zhu J. Prognostic significance and potential therapeutic target of VEGFR2 in hepatocellular carcinoma. J Clin Pathol.2011; 64(4): 343-348.
13. Chai H, Luo AZ, Weerasinghe P, and Brown RE. Sorafenib downregulates ERK/Akt and STAT3 survival pathways and induces apoptosis in a human neuroblastoma cell line. Int J Clin Exp Pathol. 2010; 3(4): 408-415.
14. Nefedova Y, Cheng P, Alsina M, Dalton WS, and Gabrilovich DI. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood. 2004; 103(9): 3503-3510.
15. Lee JY, Yu SJ, Park YG, Kim J, and Sohn J. Glycogen synthase kinase 3beta phosphorylates p21WAF1/CIP1 for proteasomal degradation after UV irradiation. Mol Cell Biol. 2007; 27(8): 3187-3198.
16. Dudgeon C, Peng R, Wang P, Sebastiani A, Yu J and Zhang L. Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3beta and NF-kappaB to suppress tumor cell growth. Oncogene. 2012; 31(46):4848-58.
17. Ding Q, Xia W, Liu JC, Yang JY, Lee DF, Xia J, Bartholomeusz G, Li Y, Pan Y, Li Z, Bargou RC, Qin J, Lai CC, Tsai FJ, Tsai CH, and Hung MC. Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell. 2005;19(2): 159- 170.
18. Hwang CY, Lee C and Kwon KS. Extracellular signalregulated kinase 2-dependent phosphorylation induces cytoplasmic localization and degradation of p21Cip1. Mol Cell Biol. 2009; 29(12): 3379-3389.
19. Wu GS. The functional interactions between the p53 and MAPK signaling pathways. Cancer Biol Ther. 2004; 3(2): 156-161.
20. Caraglia M, Giuberti G, Marra M, Addeo R, Montella L, Murolo M, Sperlongano P, Vincenzi B, Naviglio S, Prete SD, Abbruzzese A, and Stiuso P. Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. Cell Death Dis.2011; 28:2 e150.
21. Palmer DH. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(23): 2498.
22. Sonoshita M, Aoki M, Fuwa H, Aoki K, Hosogi H, Sakai Y, Hashida H, Takabayashi A, Sasaki M, Robine S, Itoh K, Yoshioka K, Kakizaki F, Kitamura T, Oshima M and Taket MM Suppression of colon cancer metastasis by Aes through inhibition of Notch signaling. Cancer Cell. 2011; 19(1): 125-137.
23. Radtke F and Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer. 2003; 3(10): 756-767.
24. Ou DL, Shen YC, Yu SL, Chen KF, Yeh PY, Fan HH, Feng WC, Wang CT, Lin LI, Hsu C and Chen A. L. Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res. 2010; 70(22): 9309-9318.
25. Rahmani M, Davis EM, Bauer C, Dent P and Grant S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl- 1 through inhibition of translation. J Biol Chem. 2005; 280(42): 35217-35227.
26. Panka, DJ, Wang W, Atkins MB and Mier JW. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspaseindependent apoptosis in melanoma cells. Cancer Res. 2006; 66(3): 1611-1619.
27. Suzuki A, Tsutomi Y, Akahane K, Araki T and Miura M. Resistance to Fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP. Oncogene. 1998;17(8): 931-939.
28. Garner E and Raj K. Protective mechanisms of p53-p21- pRb proteins against DNA damage-induced cell death. Cell Cycle. 2008; 7(3): 277-282.
29. McGill G and Fisher DE. p53 and cancer therapy: a doubleedged sword. J Clin Invest. 1999; 104(3): 223-225.
30. Zhu AX, Duda DG, Sahani DV and Jain RK. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol. 2011;8(5): 292-301.
31. Grepin R and Pages G. Molecular mechanisms of resistance to tumour anti-angiogenic strategies. J Oncol. 2010;2010: 835680.
32. Rehman AO and Wang CY. Notch signaling in the regulation of tumor angiogenesis. Trends Cell Biol. 2006;16(42): 293-300.
33. Chen SM, Liu JP, Zhou JX, Chen C, Deng YQ, Wang Y and Tao ZZ. Suppression of the notch signaling pathway by gamma-secretase inhibitor GSI inhibits human nasopharyngeal carcinoma cell proliferation. Cancer Lett. 306(1): 76-84.
34. Kondratyev M, Kreso A, Hallett RM, Girgis-Gabardo A, Barcelon ME, Ilieva D, Ware C, Majumder PK and Hassell JA. Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer. Oncogene. 2012; 31(1):93-103.
35. Elbashir SM, Lendeckel W and Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 2001; 15(2): 188-200.
36. Giovannini C, Lacchini M, Gramantieri L, Chieco P and Bolondi, L. Notch3 intracellular domain accumulates in HepG2 cell line. Anticancer Res. 2006; 26(3A): 2123-2127.